Hepatocellular carcinoma (HCC) represents the second leading cause of cancer-related mortality worldwide, claiming over 700,000 lives annually. The liver's central role in blood filtration and metabolism makes it an attractive target for drug delivery, with lipid nanoparticles (LNPs) showing particular promise due to their natural hepatic tropism. However, LNP efficacy becomes compromised in HCC environments due to inadequate understanding of liver physiology under cancerous